株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

好中球減少症:パイプライン製品の分析

Neutropenia - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 192734
出版日 ページ情報 英文 85 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.82円で換算しております。
Back to Top
好中球減少症:パイプライン製品の分析 Neutropenia - Pipeline Review, H1 2017
出版日: 2017年04月28日 ページ情報: 英文 85 Pages
概要

好中球減少症は、白血球の一種で、感染症を撃退する役目の好中球の数が異常に少ない状態を指します。兆候と症状は、発熱、頻繁な感染、口内炎、歯肉感染症、排尿障害などが見られます。

当レポートでは、好中球減少症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

好中球減少症の概要

治療薬の開発

  • パイプライン製品の概要

好中球減少症:企業で開発中の治療薬

好中球減少症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

好中球減少症:企業で開発中の製品

好中球減少症の治療薬開発に従事している企業

  • Apotex Inc.
  • Biogenomics Limited
  • Cellerant Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Limited
  • Ligand Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Prolong Pharmaceuticals, LLC
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Therapeutic Proteins International, LLC
  • 東光薬品工業
  • USV Limited

好中球減少症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

好中球減少症:最近のパイプライン動向

好中球減少症:休止中のプロジェクト

好中球減少症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9188IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H1 2017, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 4, 2, 1, 4, 3, 1, 8 and 3 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neutropenia - Overview
    • Neutropenia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Neutropenia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neutropenia - Companies Involved in Therapeutics Development
    • Adello Biologics LLC
    • Apotex Inc
    • Arven Ilac
    • BeyondSpring Pharmaceuticals Inc
    • Cellerant Therapeutics Inc
    • Cleveland BioLabs Inc
    • Coherus BioSciences Inc
    • Dr. Reddy's Laboratories Ltd
    • Eurofarma Laboratorios SA
    • Intas Pharmaceuticals Ltd
    • Ligand Pharmaceuticals Inc
    • Lupin Ltd
    • Mycenax Biotech Inc
    • Prolong Pharmaceuticals LLC
    • Richter Gedeon Nyrt
    • Sandoz International GmbH
    • USV Pvt Ltd
  • Neutropenia - Drug Profiles
    • ACN-8337 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARVMIC-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBLB-612 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LG-7455 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plinabulin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romyelocel-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamibarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neutropenia - Dormant Projects
  • Neutropenia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 25, 2017: Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
      • Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention
      • Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo
      • Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)
      • Nov 01, 2016: Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO
      • Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case
      • Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case
      • Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
      • May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication
      • Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
      • Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
      • Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
      • Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
      • Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
      • Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Neutropenia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Neutropenia - Pipeline by Adello Biologics LLC, H1 2017
  • Neutropenia - Pipeline by Apotex Inc, H1 2017
  • Neutropenia - Pipeline by Arven Ilac, H1 2017
  • Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
  • Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2017
  • Neutropenia - Pipeline by Cleveland BioLabs Inc, H1 2017
  • Neutropenia - Pipeline by Coherus BioSciences Inc, H1 2017
  • Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
  • Neutropenia - Pipeline by Eurofarma Laboratorios SA, H1 2017
  • Neutropenia - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
  • Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
  • Neutropenia - Pipeline by Lupin Ltd, H1 2017
  • Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2017
  • Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
  • Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2017
  • Neutropenia - Pipeline by Sandoz International GmbH, H1 2017
  • Neutropenia - Pipeline by USV Pvt Ltd, H1 2017
  • Neutropenia - Dormant Projects, H1 2017
  • Neutropenia - Dormant Projects, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Neutropenia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top